Home > News > Abraxis BioScience Announces Co-Promotion with AstraZeneca
April 27th, 2006
Abraxis BioScience Announces Co-Promotion with AstraZeneca
Abstract:
Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced they have entered into an agreement with AstraZeneca (NYSE:AZN) for the co-promotion of Abraxis' proprietary drug ABRAXANE(R), in the United States for a term of five and a half years.
Source:
Abraxis BioScience
Bookmark:
| Related News Press |
Nanomedicine
Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Self-propelled protein-based nanomotors for enhanced cancer therapy by inducing ferroptosis June 6th, 2025
Announcements
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Quantum computers simulate fundamental physics: shedding light on the building blocks of nature June 6th, 2025
A 1960s idea inspires NBI researchers to study hitherto inaccessible quantum states June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||